Literature DB >> 21864180

Abiraterone and increased survival in metastatic prostate cancer.

Chris Parker, Oliver Sartor.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21864180     DOI： 10.1056/NEJMc1107198

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  5 in total

1.  Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.

Authors:  Yu-Ning Wong; Judith Manola; Gary R Hudes; Bruce J Roth; Judd W Moul; Andrea M Barsevick; Richard M Scher; Michael J Volk; David J Vaughn; Stephen D Williams; Michael J Fisch; David Cella; Michael A Carducci; George Wilding
Journal:  Clin Genitourin Cancer       Date:  2017-10-16       Impact factor: 2.872

Review 2.  Advances in neuroendocrine prostate cancer research: From model construction to molecular network analyses.

Authors:  Xue Shui; Rong Xu; Caiqin Zhang; Han Meng; Jumei Zhao; Changhong Shi
Journal:  Lab Invest       Date:  2021-12-22       Impact factor: 5.662

Review 3.  Targeting signaling pathways in prostate cancer: mechanisms and clinical trials.

Authors:  Yundong He; Weidong Xu; Yu-Tian Xiao; Haojie Huang; Di Gu; Shancheng Ren
Journal:  Signal Transduct Target Ther       Date:  2022-06-24

Review 4.  Emerging role of tumor cell plasticity in modifying therapeutic response.

Authors:  Siyuan Qin; Jingwen Jiang; Yi Lu; Edouard C Nice; Canhua Huang; Jian Zhang; Weifeng He
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 5.  Prostate cancer and therapeutic challenges.

Authors:  Yousef MohammedRabaa Hawsawi; Samar Abdullah Zailaie; Atif Abdulwahab A Oyouni; Othman Rashed Alzahrani; Osama Mohamed Alamer; Saad Ali S Aljohani
Journal:  J Biol Res (Thessalon)       Date:  2020-12-10       Impact factor: 1.889
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.